

Anti-human CD19 Antibody (8G840)

Product Details

| | |
|-------------------|--------------------------------------|
| Ig Type: | Mouse IgG1 |
| Reactivity: | Human |
| Molecular Weight: | Theoretical: 59 kDa. Actual: 90 kDa. |
| Clone: | 8G840 |
| Purification: | Protein G purified |

Applications

| | |
|--------------------|--|
| Verified Activity: | scatter diagram showing peripheral blood lymphocytes stained with TMAB-07390. The cells were incubated with the antibody (TMAB-07390, 5 µl/Test) for 30 min at 22°C. The secondary antibody used for 40 min at room temperature Acquisition of >10,000 events was performed. |
| Application: | FCM |
| Recommended | FCM: 1µg/Test |

Properties

| | |
|----------------------|---|
| Stability & Storage: | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Shipping: | Shipping with blue ice. |

Antigen Details

| | |
|------------------|--|
| Immunogen: | KLH conjugated synthetic peptide: human CD19 |
| Antigen Species: | Human |
| Gene ID: | 930 |
| Uniprot ID: | P15391 |

Research Background

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481